Identification of a CpG island methylator phenotype in adrenocortical carcinomas

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 1, 2013, Pages

  Barreau, Olivia ^a,b,c   Assié, Guillaume ^a,c   Wilmot Roussel, Hortense ^a,c   Ragazzon, Bruno ^a   Baudry, Camille ^a,c   Perlemoine, Karine ^c   René Corail, Fernande ^c   Bertagna, Xavier ^a,c,d   Dousset, Bertrand ^a,c   Hamzaoui, Nadim ^a   Tissier, Frédérique ^a,c   De Reynies, Aurélien ^b   Bertherat, Jérôme ^a,c  

^a Hôpital Cochin ^*  (France)

^b Cartes d'Identité des Tumeurs Program Ligue Nationale Contre le Cancer   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSTITUT NATIONAL DU CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME;

ADENOMA; ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA PROBE; FEMALE; G0S2 GENE; GENE CLUSTER; GENE EXPRESSION; H19 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NDRG2 GENE; PHENOTYPE; PLAGL 1 GENE; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL ADENOMA; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; YOUNG ADULT;

EID: 84872074776     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2993     Document Type: Article

References (44)

1. Fassnacht M, Allolio B 2009 Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 23:273-289
2. Bertherat J, Bertagna X 2009 Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab 23:261-271
3. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G, Hammer G 2009 Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 15:668-676
4. de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E, Bertherat J 2009 Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27:1108-1115
5. Szabó PM, Tamá si V, Molná r V, Andrá sfalvy M, Tömböl Z, Farkas R, Kövesdi K, Patócs A, Tóth M, Szalai C, Falus A, Rácz K, Igaz P 2010 Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed. Oncogene 29:3163-3172
6. Ragazzon B, Libé R, Gaujoux S, Assié G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reyniès A, Bertherat J 2010 Transcriptome analysis reveals that p53 and β-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 70:8276-8281
7. Kulis M, Esteller M 2010 DNA methylation and cancer. Adv Genet 70:27-56
8. Issa JP 2004 CpG island methylator phenotype in cancer. Nat Rev Cancer 4:988-993
9. Van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, Van Marck EA, Pauwels P, Vermeulen PB, Dirix LY, Van Laere SJ 2010 Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One 5:e12616
10. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP 1999 CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96:8681-8686
11. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, Tollenaar RA, Laird PW 2012 Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 22:271-282
12. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW 2006 CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787-793
13. Gao ZH, Suppola S, Liu J, Heikkilä P, Jänne J, Voutilainen R 2002 Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. J Clin Endocrinol Metab 87:1170-1176
14. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F, Le Bouc Y 1994 Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78:1444-1453
15. Rechache NS, Wang Y, Stevenson HS, Killian JK, Edelman DC, Merino M, Zhang L, Nilubol N, Stratakis CA, Meltzer PS, Kebebew E 2012 DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J Clin Endocrinol Metab 97:1004-1013
16. Fonseca AL, Kugelberg J, Starker LF, Scholl U, Choi M, Hellman P, Akerström G, Westin G, Lifton RP, Björklund P, Carling T 2012 Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer 51:949-960
17. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B 2009 Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115:243-250
18. Weiss LM 1984 Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8:163-169
19. Terzolo M, Alì A, Osella G, Reimondo G, Pia A, Peretti P, Paccotti P, Angeli A 2000 The value of dehydroepiandrosterone sulfate measurement in the differentiation between benign and malignant adrenal masses. Eur J Endocrinol 142:611-617
20. Du P, Kibbe WA, Lin SM 2008 lumi: a pipeline for processing Illumina microarray. Bioinformatics 24:1547-1548
21. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, Lin SM 2010 Comparison of β-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11:587
22. Team RDC 2011 R: a language and environment for statistical computing. R Foundation for Statistical Computing, ed. Vienna: R Foundation for Statistical Computing
23. Huang da W, Sherman BT, Lempicki RA 2009 Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44-57
24. Deaton AM, Bird A 2011 CpG islands and the regulation of transcription. Genes Dev 25:1010-1022
25. Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J, Brown R 2001 Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158:1121-1127
26. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP 1999 Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59:5438-5442
27. Li B, Liu W, Wang L, Li M, Wang J, Huang L, Huang P, Yuan Y 2010 CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma. Ann Surg Oncol 17:1917-1926
28. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, Goggins M 2000 Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 60:1835-1839
29. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR, Danenberg KD, Danenberg PV, Laird PW, Skinner KA 2000 Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 60:5021-5026
30. McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, Ragoussis J, Clarke NW, Brown MD, Kishida T, Yao M, Latif F, Maher ER 2009 CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer 8:31
31. Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, Morton DL, Hoon DS 2009 CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15:1801-1807
32. Gumy-Pause F, Pardo B, Khoshbeen-Boudal M, Ansari M, Gayet-Ageron A, Sappino AP, Attiyeh EF, Ozsahin H 2012 GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma. Genes Chromosomes Cancer 51:174-185
33. Chan QK, Khoo US, Chan KY, Ngan HY, Li SS, Chiu PM, Man LS, Ip PP, Xue WC, Cheung AN 2005 Promoter methylation and differential expression of π-class glutathione S-transferase in endometrial carcinoma. J Mol Diagn 7:8-16
34. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG 2004 GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 91:540-552
35. Noda E, Maeda K, Inoue T, Fukunaga S, Nagahara H, Shibutani M, Amano R, Nakata B, Tanaka H, Muguruma K, Yamada N, Yashiro M, Ohira M, Ishikawa T, Hirakawa K 2012 Predictive value of expression of ERCC1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. Hepatogastroenterology 59:130-133
36. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, et al. 2012 Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189-2197
37. Welch C, Santra MK, El-Assaad W, Zhu X, Huber WE, Keys RA, Teodoro JG, Green MR 2009 Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2. Cancer Res 69:6782-6789
38. Varrault A, Ciani E, Apiou F, Bilanges B, Hoffmann A, Pantaloni C, Bockaert J, Spengler D, Journot L 1998 hZAC encodes a zinc finger protein with antiproliferative properties and maps to a chromosomal region frequently lost in cancer. Proc Natl Acad Sci USA 95:8835-8840
39. Liu N, Wang L, Liu X, Yang Q, Zhang J, Zhang W, Wu Y, Shen L, Zhang Y, Yang A, Han H, Zhang J, Yao L 2007 Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun 358:164-169
40. Liu J, Li XD, Vaheri A, Voutilainen R 2004 DNA methylation affects cell proliferation, cortisol secretion and steroidogenic gene expression in human adrenocortical NCI-H295R cells. J Mol Endocrinol 33:651-662
41. Suh I, Weng J, Fernandez-Ranvier G, Shen WT, Duh QY, Clark OH, Kebebew E 2010 Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells. Arch Surg 145:226-232
42. van Vlodrop IJ, Niessen HE, Derks S, Baldewijns MM, van Criekinge W, Herman JG, van Engeland M 2011 Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res 17:4225-4231
43. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A 2009 Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930-935
44. Huang Y, Pastor WA, Shen Y, Tahiliani M, Liu DR, Rao A 2010 The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One 5:e8888